EMA Reviews Injectable Iron Drugs Over Bone-Risk Reports

EMA's Pharmacovigilance Risk Assessment Committee has opened a formal safety review covering every injectable iron-containing medicine authorized in the EU, after reports of severe phosphate loss and bone-softening in patients treated with them — in some cases after only one or two doses, and in patients with none of the recognized risk factors. The review, opened under Article 31 of Directive 2001/83/EC at the request of the Austrian medicines agency (BASG), was discussed at PRAC's 31 August–3 September meeting and made public around 4 September.

A known risk, reported in an unfamiliar pattern

Hypophosphataemia — abnormally low blood phosphate — is not a new finding for this drug class. It is a recognized side effect of ferric carboxymaltose, and when it persists it can progress to hypophosphataemic osteomalacia, a softening of the bones caused by chronically low phosphate. What has changed, according to EMA, is the pattern of recent reports: cases turning up after just one or two infusions, and in patients who lack the risk factors clinicians have historically used to flag who needs closer monitoring. That combination is what pushed PRAC to ask whether the risk-minimization measures already in place — largely inherited from an earlier EU review of intravenous iron products in 2013, which focused on the risk of allergic reactions rather than phosphate loss — are still adequate.

Why the whole drug class, not just one brand

The review was requested over ferric carboxymaltose specifically, but PRAC widened its scope after similar hypophosphataemia cases turned up with other injectable iron-containing medicines. The result is a review that spans essentially every parenteral iron product used in EU practice: ferric carboxymaltose (sold as Ferinject or Injectafer), ferric derisomaltose (Monofer or Monoferric), iron dextran, ferric gluconate, ferric hydroxide polymaltose complex, and iron sucrose. Oral iron formulations are explicitly excluded from the review — they deliver far less iron over time than an infusion does, which EMA says makes them considerably less likely to cause the same phosphate disturbance.

That breadth matters operationally. These products sit across oncology, nephrology, gastroenterology, and obstetric practice as a default treatment for iron-deficiency anemia when oral iron fails or is not tolerated. A label change or new monitoring requirement that applies across the class, rather than to a single brand, would touch prescribing protocols well beyond wherever the original signal was reported.

The referral track most of these products are on

Because most injectable iron products reached the EU market through national authorization procedures rather than the EU's centralized process, PRAC's eventual recommendation does not itself change any label. It goes instead to the Coordination Group for Mutual Recognition and Decentralised Procedures — Human (CMDh), the body that adopts a single position applying across EU member states plus Iceland, Liechtenstein, and Norway. Possible outcomes range from enhanced monitoring recommendations and updated prescribing information to additional risk-minimization measures such as new contraindications or dosing limits. PRAC has not set out a timeline for concluding the review; the committee's meeting highlights describe the assessment as ongoing.